-
-
-
-
-
-
-
Scholar Rock Holding Corp. (SRRK) Tops Q2 EPS by 1c
-
-
-
-
-
-
-
Scholar Rock resubmits drug application to FDA for SMA treatment
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Raised to $53 at Barclays
-
-
-
-
-
-
-
Citi Starts Scholar Rock (SRRK) at Buy
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Lowered to $44 at Barclays
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Lowered to $45 at BMO Capital
-
460,935 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

